Abstract
1. The effects of levodopa alone (50 mg kg-1) and levodopa (10 mg kg-1) plus benserazide (50 mg kg-1) were tested on the levels of dopa, dopamine, 3-methoxytyrosine (3-MT), 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), measured by h.p.l.c. with electrochemical detection, in samples of plasma, CSF, urine, striatum and hypothalamus of rats taken 30 min after injection. Levodopa plus benserazide produced significantly higher levels of dopa in plasma and brain than levodopa alone and reduced the peripheral synthesis and metabolism of dopamine. 2. When given chronically over 6 weeks the advantages of adding benserazide (50 mg kg-1 day-1) to levodopa (40 mg kg-1 day-1) were less marked and although more dopamine was present in the striatum than with levodopa given alone (200 mg kg-1 day-1) there was no evidence of any increase in its metabolites (HVA and DOPAC) and therefore of its turnover and utilisation. 3. The most striking effect of chronic treatment with levodopa plus benserazide was the appearance of large quantities of 3-MT in plasma, CSF and brain. 4. When levodopa alone, or levodopa plus benserazide, was given as an acute challenge to animals receiving the same treatment chronically, it was found that ...Continue Reading
References
Dec 1, 1977·Acta Neurologica Scandinavica·C FeuersteinM Tanche
Jan 1, 1976·Drugs·M T Roberts
Jan 1, 1976·Drugs·R M PinderG S Avery
Feb 1, 1989·Clinical Neuropharmacology·M R LuquinJ A Obeso
May 1, 1974·Neurology·S Fahn
May 1, 1970·European Journal of Pharmacology·I KurumaA Pletscher
Aug 19, 1967·Nature·G BartholiniA Pletscher
Mar 1, 1983·Neurology·J J GervasJ G de Yébenes
Jul 1, 1983·Neurology·E MelamedJ Rosenthal
Feb 23, 1984·The New England Journal of Medicine·J G NuttJ L Anderson
Jun 1, 1984·Brain : a Journal of Neurology·R J HardieG M Stern
Citations
Sep 7, 2001·Drug and Alcohol Dependence·K YuiT Ishiguro
Feb 11, 2000·Drug and Alcohol Dependence·K YuiT Ishiguro
Jul 1, 2000·Addiction Biology·K YuiT Ishiguro
Mar 1, 1992·Acta Physiologica Scandinavica·P Hansell, M Sjöquist
Jan 27, 2009·European Journal of Pharmacology·Naoko MatsushitaYoshio Goshima
Sep 17, 2008·International Journal of Radiation Oncology, Biology, Physics·Silvia CapuaniFrancesco S Pastore
Nov 16, 2004·Annals of the New York Academy of Sciences·Kunio YuiShigenori Ikemoto
Jun 23, 2012·Neuropharmacology·Philippe HuotJonathan M Brotchie
Oct 2, 2003·Journal of Clinical Psychopharmacology·Kunio YuiSatoshi Kato
Apr 19, 2000·Journal of Clinical Psychopharmacology·K YuiY Kamata
Jul 10, 2002·Annals of the New York Academy of Sciences·Kunio YuiKimihiko Goto
Nov 21, 2000·Annals of the New York Academy of Sciences·K YuiS Ikemoto
Mar 3, 2018·Neuroscience·Cynthia A Kelm-NelsonMichelle R Ciucci
May 8, 2021·Naunyn-Schmiedeberg's Archives of Pharmacology·De-Qi JiangJing-Yi Qiao